Reserve your spot today for this Virtual Satellite Symposium!

Jointly provided by     This activity is supported by an independent educational grant from Merck & Co., Inc. Wednesday, October 21, 2020 9:00 AM - 10:30 AM ET Click here to register!   Learn About Increasing impact of C. Difficile Infection (CDI) Latest guidelines, updates and management strategies for novel treatment options Best practices in benefit design to control the costs of CDI   Expert Faculty Presenters James Kenney, Jr., RPh, MBA Founder and President JTKenney, LLC Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC A. Krishna Rao, MD, MS Assistant Professor Division of Infectious Diseases Department of Internal Medicine University of Michigan Medical School   Who Should Attend? This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending AMCP Nexus 2020 virtually.   Statement of Need/Program Overview The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000. A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations. In addition, the faculty panel, including managed care experts, will review guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.   Educational Objectives At the conclusion of this activity, participants should be able to demonstrate improved ability to: Review the epidemiology and prevalence of C. Difficile Infection (CDI) Evaluate novel treatment options for primary and recurrent CDI Apply guideline-based management strategies for CDI Illustrate avoidable costs related to CDI treatment management that can impact benefit design and coverage decision-making   Agenda Date and Time Wednesday, October 21, 2020 9:00 AM - 10:30 AM ET 9:00 AM Pre-Activity Learning Assessment and Opening Comments/Overview James Kenney, Jr., RPh, MBA 9:05 AM CDI Clinical Update – Why the Increase? A. Krishna Rao, MD, MS 9:35 AM Care Management Strategies to Address the Rising Costs of CDI Edmund Pezalla, MD, MPH 9:55 AM CDI Case Scenarios and Best Practice Recommendations James Kenney, Jr., RPh, MBA 10:15 AM Audience Q&A Session 10:25 AM Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation 10:30 AM Adjournment

Accreditation Statements

Physician Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacy Credit Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: 0816-9999-20-163-L01-P This activity is certified as Knowledge-based CPE.

Disclosure of Conflicts of Interest It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Hardware/Software Requirements Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up. Fee Information There is no fee for this educational activity. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.